Skip to main content
Premium Trial:

Request an Annual Quote

Osmetech and Epidauros to Co-Develop Companion Dx Products; HIV, Cancer to Be a Focus

NEW YORK (GenomeWeb News) — Osmetech and Epidauros plan to jointly develop companion diagnostics for pharmaceuticals and pharmacogenomic biomarkers, the companies said today.

Under the terms of the agreement, Osmetech will use Epidauros’ biomarkers to develop and market assays for its eSensor array systems, the companies said.

Osmetech CEO James White said the agreement gives the company “access to a very strong pipeline” of companion diagnostics for biomarkers and pharmaceutical development. He said the company will use these in its efforts to expand its market position by “linking the drug to the diagnostic.”

Epidauros CEO Michael Lutz said the deal will spur advances not only in the company’s biomarker pipeline, “but also any personalized medicine-related marker our pharma partners may want to develop into molecular diagnostic tests, in particular in the fields of HIV and oncology.”

This is not the first deal between the two companies. In October 2006 Osmetech said it will use Epidauros’ CYP450 2D6 biomarker patent to expand into pharmacogenomics testing.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.